EndoGene.Bio develops non-invasive diagnostic tests for endometriosis by analyzing epigenetic markers found in menstrual blood. This technology provides a reliable method for early detection of endometriosis, addressing the challenges of delayed diagnosis and improving patient outcomes.
Funding
$110K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Endometriosis diagnosis is often delayed due to the need for invasive surgical procedures, leading to prolonged suffering and delayed treatment for affected individuals. Current diagnostic methods lack the sensitivity and accessibility needed for early and widespread screening.
Solution
EndoGene.Bio is developing non-invasive diagnostic tests for endometriosis utilizing epigenetic markers detectable in menstrual blood samples. This approach aims to provide a more accessible and reliable method for early detection, reducing the time to diagnosis and enabling earlier intervention. By analyzing specific epigenetic signatures, the test can identify the presence of endometriosis without the need for surgery. The company's focus is on improving patient outcomes through timely and accurate diagnosis.
Target Audience
The primary target audience includes women experiencing symptoms suggestive of endometriosis, as well as gynecologists and other healthcare providers seeking improved diagnostic tools for this condition.
Features
- Analysis of epigenetic markers in menstrual blood samples
- Non-invasive diagnostic approach, eliminating the need for surgical procedures
- Early detection of endometriosis, enabling timely intervention
- Identification of specific epigenetic signatures associated with endometriosis